The new $25m fund will have a multi-year commitment to invest in early-stage startups developing animal health therapies and related technologies.
Pharmaceutical company Elanco Animal Health is launching a dedicated corporate VC unit to invest in early-stage animal health startups. The $25m fund, called Elanco Ventures, is scheduled to launch in late 2026 and will mark a formal expansion of Elanco’s external innovation strategy.
Elanco Ventures will be overseen by Eric Steager, an experienced corporate venture investor, and will target companies at the pre-seed, seed and series A stages.
The fund will initially focus on investing in therapeutic innovations and enabling technologies across animal health.
While its primary remit is the animal health sector, Elanco said it may also consider opportunities linked to the broader “One Health” ecosystem, which spans animal, human and environmental health.
The venture platform will be closely connected to the One Health Innovation District in Indianapolis, an innovation hub anchored by Elanco and Purdue University that aims to bring together researchers, startups and life sciences organisations. The company said the district would provide access to partnerships and emerging technologies relevant to the fund’s investment activities.
Elanco has been taking an active role in innovation having, for example, helped build and spin out Athian, an agritech software startup. However, the VC unit would allow the company to work more broadly with external startups.
“Innovation is happening outside of the boundaries of any single company. Elanco Ventures allows us to strategically leverage the startup landscape to expand our visibility into a range of emerging technologies that help us meet pet owners’ evolving expectation of care and the increasing global demand for protein,” said Jeff Simmons, president and chief executive at Elanco.
The launch comes as corporate venture investors across healthcare and life sciences increasingly use dedicated investment vehicles to access early-stage innovation and strengthen links with startup ecosystems.
For animal health companies, venture investing has become a way to monitor emerging therapeutic platforms, digital technologies and adjacent health sectors without relying solely on internal development programmes.
With a defined fund commitment, a dedicated management structure and a focus on early-stage investing, Elanco Ventures represents a more formal approach to venture investing for the company as it seeks exposure to new technologies shaping the future of animal health.
